Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT06147362
Overview
The gastrin-releasing peptide receptor (GRPR), also known as bombesin receptor subtype II (BB2), is a member of the G protein-coupled receptor family of bombesin receptors. GRPR is over-expressed in various types of human tumors. RM26, a GRPR antagonist with high affinity, was discovered by peptide backbone modification of bombesin analogues. To target gastrin-releasing peptide receptor in human neoplastic cells NOTA-PEG2-RM26 was synthesised and then labeled with 68Ga. An open-label whole-body PET/ CT study was designed to investigate the safety and dosimetry of 68Ga-NOTA-PEG2-RM26 and to assess its clinical diagnostic value in patients with cancer.
Sponsor
Karolinska University HospitalPhase
Phase 1
Contacts
Antonios Tzortzakakis, MD, PhD
antonios.tzortzakakis@regionstockholm.se
08-123 70 000
Annette Fransson-Andreo-Hernandez, PhD
annette.fransson-andreo-hernandez@regionstockholm.se
+468 517 753 74
ClinicalTrials.gov
NCT06147362Drug / Compound
Help us improve your experience